An international, double-blind, randomised, placebo-controlled phase IIb trial to assess the efficacy, safety, and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis

Trial Profile

An international, double-blind, randomised, placebo-controlled phase IIb trial to assess the efficacy, safety, and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs GNbAC1 (Primary)
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CHANGE-MS
  • Sponsors GeNeuro
  • Most Recent Events

    • 13 Jul 2017 Planned number of patients changed from 260 to 270.
    • 04 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Dec 2016 According to a Servier media release, primary results after 6 months of this trial are expected in Q4 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top